Benzinga | Oct 1, 2020 07:33AM EDT

Cyclerion Says Expects To Communicate Top Line Results From Olinciguat Phase 2 Strong Study In Sickle Cell Disease Patients & IW-6463 Translational Pharmacology In The Coming Weeks

On October 1, 2020, Cyclerion Therapeutics, Inc. provided an update on the timing of disclosing top line results of two clinical trials: olinciguat Phase 2 STRONG study in sickle cell disease patients, and IW-6463 translational pharmacology study, conducted in elderly healthy subjects, to support further development in serious central nervous system (CNS) diseases. As a result of some recent COVID-19 related operational delays in obtaining certain study data, Cyclerion continues to perform analyses of data from both studies, and expects to communicate top line results from both these studies in the coming weeks.